Another Disappointing Year for Drug Approvals
This article was originally published in RPM Report
Executive Summary
New molecular entity approvals dipped in 2010 and Innovative Commercial Therapies dropped even more sharply. Add to that a significant drop in filings in 2010 and it is hard to be optimistic about a turnaround in approval numbers any time soon.